WHO ICTRP trial
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid…
EUCTR2013-003780-65-IT · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2013-003780-65-IT |
|---|---|
| Public title | Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis |
| Scientific title | A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects with Moderate to Severe Active Rheumatoid Arthritis who have Experienced an Inadequate Response to TNF inhibitors |
| Primary sponsor | Bristol-Myers Squibb International Corporation |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Countries | France;United States;Hungary;Czech Republic;Mexico;Canada;Argentina;Australia;South Africa;Japan;Italy |
| Conditions | Rheumatoid Arthritis MedDRA version: 14.1 Level: LLT Classification code 10066578 Term: Progression of rheumatoid arthritis System Organ Class: 100000004859 MedDRA version: 14.1 Level: LLT Classification code 10060732 Term: Rheumatoid… |
| Interventions | Product Name: CLAZAKIZUMAB Product Code: BMS-945429 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: CLAZAKIZUMAB CAS Number: 1236278-28-6 Current Sponsor code: BMS945429 Concentration unit: mg/ml… |
| Registration date | Mar 12, 2013 |
| Target size | 240 |
| Secondary IDs | IM133-066 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: